Rose-Hip Vital receives Theraputic Goods Authority safety tick for use
The Therapeutic Goods Association of Australia has recently given Rosa Canina (Rosehip) produced by Rose-Hip Vital, advanced listing as a substance not only suitable for the reduction in joint inflammation, swelling, mobility and pain relating to osteoarthritis (OA) and rheumatism, but also for overall wellness.
Rosehip effectively targets the pathways that cause OA pain and discourages large numbers of white blood cells from accumulating in the affected joint. It is these white blood cells which are responsible, both directly and indirectly, for causing OA pain. Rosehips are widely used in Europe for OA treatment.
The Journal of Rheumatology (Aug 2005) reported that, of 94 OA patients in a study conducted at the University of Copenhagen, Denmark, 82% reported a reduction in pain after three weeks treatment, using a specially grown rosehip product. The research also showed pain was alleviated to an extent that there was significant reduction in usage of traditional painkillers. In addition, after a three month period, there was increased joint mobility, reduction in joint stiffness on waking, better management of joint pain, and relief from arthritic pain.
Additional lifestyle benefits claimed include increased energy and general wellbeing as well as improved sleep when affected by joint pain and discomfort leading to a reduction in consumption of traditional painkillers by up to 50%. There are no reported side effects for people with allergies and diabetics.
